Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus

Jönsen, Andreas; Nilsson, Sara; Ahlqvist, Emma; Svennungsson, Elisabet; Gunnarsson, Iva; Eriksson, Karin G.; Bengtsson, Anders; Zickert, Agneta; Eloranta, Maija-Leena; Truedsson, Lennart; Ronnbloom, Lars; Nordmark, Gunnar; Sturfelt, Gunnar; Blom, Anna

Published in:
Arthritis Research and Therapy

DOI:
10.1186/ar3539

2011

Link to publication

Citation for published version (APA):
Jönsen, A., Nilsson, S., Ahlqvist, E., Svennungsson, E., Gunnarsson, I., Eriksson, K. G., Bengtsson, A., Zickert, A., Eloranta, M-L., Truedsson, L., Ronnbloom, L., Nordmark, G., Sturfelt, G., & Blom, A. (2011). Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus. Arthritis Research and Therapy, 13(6), [R206]. https://doi.org/10.1186/ar3539

Total number of authors:
14
Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus

Andreas Jönsen1, Sara C Nilsson2, Emma Ahlqvist3, Elisabet Svennungsson4, Iva Gunnarsson4, Karin G Eriksson5, Anders Bengtsson1, Agneta Zickert4, Maija-Leena Eloranta3, Lennart Truedsson6, Lars Rönnblom5, Gunnel Nordmark5, Gunnar Sturfelt1 and Anna M Blom2*

Abstract

Introduction: Inherited deficiencies of several complement components strongly predispose to systemic lupus erythematosus (SLE) while deficiencies of complement inhibitors are found in kidney diseases such as atypical hemolytic uremic syndrome (aHUS).

Methods: The exons of complement inhibitor genes CD46 and CFH (factor H) were fully sequenced using the Sanger method in SLE patients with nephritis originating from two cohorts from southern and mid Sweden (n = 196). All identified mutations and polymorphisms were then analyzed in SLE patients without nephritis (n = 326) and in healthy controls (n = 523).

Results: We found nonsynonymous, heterozygous mutations in CFH in 6.1% patients with nephritis, in comparison with 4.0% and 5.4% in patients without nephritis and controls, respectively. No associations of SLE or nephritis with common variants in CFH (V62I/Y402H/E936D) were found. Furthermore, we found two nonsynonymous heterozygous mutations in CD46 in SLE patients but not in controls. The A353V polymorphism, known to affect function of CD46, was found in 6.6% of nephritis patients versus 4.9% and 6.1% of the non-nephritis SLE patients and controls. The presence of mutations in CD46 and CFH did not predispose to SLE or nephritis but was associated with earlier onset of nephritis. Furthermore, we found weak indications that there is one protective and one risk haplotype predisposing to nephritis composed of several polymorphisms in noncoding regions of CD46, which were previously implicated in aHUS.

Conclusions: SLE nephritis is not associated with frequent mutations in CFH and CD46 as found in aHUS but these may be modifying factors causing earlier onset of nephritis.

Introduction

Systemic lupus erythematosus (SLE) is a complex and heterogeneous autoimmune disease affecting multiple organs that is characterized by circulating antibodies to nuclear antigens. Many studies have demonstrated a strong genetic component to SLE. Several susceptibility loci have recently been identified in genes encoding proteins involved in many immunological pathways [1], including B-cell signaling and development, cytokine production [2], the type I interferon pathway [3,4], signaling through Toll-like receptors, and neutrophil function [5].

One of the immune system cascades involved in the etiopathogenesis of SLE is the complement system. Complement is a pivotal part of the innate immunity, protecting the host from infections and participating in many processes that maintain tissue homeostasis [6]. In active SLE, immune complex deposition and...
complement activation contribute to tissue inflammation and damage. On the other hand, inherited deficiencies of complement components such as C1, C2 and C4 strongly predispose to the development of SLE [7]. This predisposition may be because an intact complement system is important for opsonization and clearance of apoptotic and necrotic cells as well as immune complexes, and thus is important for the prevention of autoimmunity. Additionally, complement is involved in B-cell maturation, differentiation and tolerance. Complement is also involved in microbial defense and thus may be related to SLE exacerbations caused by infections.

Complement is a proteolytic cascade that must be tightly regulated by several soluble and membrane-bound inhibitors in order to prevent damage to own tissues. These inhibitors are typically built of complement control protein (CCP) domains and are mainly encoded by the RCA (regulators of complement activation) gene cluster located on the long arm of chromosome 1. The present study was focused on the genes encoding two such proteins: CD46 encoding membrane cofactor protein (MCP), and CFH encoding factor H (FH). MCP is a cell-bound inhibitor, while FH circulates in blood. Nearly all human cell types, with the exception of erythrocytes, express MCP. This protein acts as a cofactor to serine protease factor I (F1), which is able to degrade activated complement components C3b and C4b and thereby to inhibit all pathways of complement. MCP is composed of four CCP domains followed by a serine/threonine-rich region, a transmembrane domain and a small intracellular domain. FH is the major soluble inhibitor of the alternative pathway of complement, serving as a cofactor to F1 in degradation of C3b. FH is composed of 20 CCP domains, some of which have a very high degree of homology with FH-related proteins 1 to 5 (CFHR1 to CFHR5).

Immune complexes generated in SLE can be passively trapped in kidney glomeruli but also directly bound to glomerular structures, causing a wide range of renal lesions including glomerulonephritis, vasculopathy and tubulointerstitial disease [8]. Defects in adequate inhibition of complement caused by inherited or acquired deficiencies of complement inhibitors could thus be involved in development and exacerbations of SLE nephritis. Importantly, inherited defects in complement inhibitors have already been associated with several kidney diseases. Complete deficiency of FH leads to membranoproliferative glomerulonephritis [9], complete deficiency of FI results in glomerulonephritis [10], while heterozygous mutations in genes encoding FH, FI and MCP result in atypical hemolytic uremic syndrome (aHUS).

Because of the well-established role of complement in SLE and the frequent genetic deficiencies of complement inhibitors in kidney diseases, we hypothesized that mutations or polymorphisms in complement inhibitors may be associated with SLE, and in particular with SLE nephritis. Recent genome-wide association studies have been successful in identifying a number of SLE-associated genes [1,11-13]. However, these studies only investigated the effect of single common variants. In the present study we performed Sanger sequencing of all exons in the CD46 and CFH genes in two cohorts of SLE patients collected in southern and mid Sweden to identify rare variants with a potential effect on SLE and SLE nephritis. We also analyzed the effect of haplotypes in CFH and CD46 that are known to affect related traits.

Materials and methods

Patients and controls

We studied two cohorts of unrelated SLE patients originating from southern Sweden (Lund) and mid Sweden (Uppsala and Stockholm). The Lund cohort consisted of 164 unselected consecutive SLE patients (21 men/143 women) treated at Skåne University Hospital in Lund and who agreed to participate in the study. The Uppsala cohort consisted of 35 SLE patients (four men/31 women) with nephritis and 35 age-matched SLE patients without nephritis (four men/31 women) all treated at the University Hospital in Uppsala. The Stockholm cohort of 288 patients (30 men/258 women) included unselected consecutive SLE patients treated at Karolinska University Hospital in Stockholm. Because of the very close geographical vicinity of Uppsala and Stockholm these two cohorts were pooled into one cohort (mid Sweden) composed finally of 358 SLE patients (38 men/320 women).

All SLE patients included in the study fulfilled four or more of the American College of Rheumatology classification criteria for SLE [14]. The majority (90.5%) of patients were Caucasians. The clinical characteristics of the patients are presented in Table 1. Additionally, 186 (37 men/149 women; southern Sweden) and 70 (8 men/62 women; Uppsala) healthy blood donors matched for sex and age were enrolled as controls. Controls (n = 267) originating from Stockholm (20 men/247 women) were individually sex-matched and age-matched population controls.

The local ethic committees of Lund University and Uppsala University and the regional ethical review board in Stockholm approved the study, and subjects’ consent was obtained according to the Declaration of Helsinki.

Genotyping

DNA sequencing using the Sanger dideoxy method was performed by Polymorphic DNA Technologies (Alameda, CA, USA). All exons including at least 20 flanking intron nucleotides were analyzed for CFH and CD46.
in patients with nephritis (southern Sweden, \( n = 43 \); mid Sweden, \( n = 153 \)). Thereafter, all exons containing mutations and polymorphisms identified in \( CFH \) and \( CD46 \) in the previous step were also sequenced in SLE patients without kidney involvement (southern Sweden, \( n = 121 \); mid Sweden, \( n = 205 \)) as well as controls (southern Sweden, \( n = 186 \); mid Sweden, \( n = 337 \)). Finally, some synonymous SNPs in \( CD46 \) that were previously associated with aHUS (rs2796267, rs2796268, rs1962149, rs859705 and rs7144) and form the \( CD46_{gaag} \) haplotype were genotyped in all SLE patients and controls. The mean base call rate for the project was 99%. All identified SNPs were in Hardy-Weinberg equilibrium (\( P > 0.01 \)). The protein numbering system used includes signal sequences (that is, the first methionine numbered as amino acid 1).

### Table 1 Patient characteristics

| Disease | Southern Sweden | Mid Sweden |
|---------|-----------------|------------|
| Number of patients | 164 | 358 |
| Women | 143 (87) | 320 (89) |
| Age at diagnosis (years) | 46.0 ± 13.2 | 31.8 ± 13.6 |
| Age at nephritis onset (years) | 33.8 ± 14.6 | 33.6 ± 14.9 |
| SLE duration (years) | 160 ± 9.7 | 17.7 ± 1.10 |
| Number of SLE criteria | 5.9 (4 to 10) | 5.8 (4 to 10) |
| Malar rash | 95 (58) | 190 (53) |
| Discoid rash | 61 (37) | 59 (16) |
| Photosensitivity | 116 (71) | 195 (54) |
| Oral ulcer | 42 (26) | 114 (32) |
| Arthritis | 132 (80) | 299 (84) |
| Serositis | 88 (54) | 158 (44) |
| Neurological disorder | 15 (9) | 45 (13) |
| Hematological disorder | 87 (53) | 241 (61) |
| Immunological disorder | 121 (74) | 265 (74) |
| Antinuclear antibodies | 164 (100) | 356 (99) |

Data presented as \( n (\%) \), mean ± standard deviation or mean (range). SLE, systemic lupus erythematosus.

### Table 2 Nonsynonymous mutations found in \( CD46 \) and \( CFH \) genes

| Gene | SNP number | Amino acid* | cDNA ATG + 1 | Genomic DNA | Domain | Frequency in SLE patients with/without nephritis (% (n)) | Frequency in controls (%(n)) | Disease association/function | References |
|------|------------|-------------|--------------|-------------|--------|------------------------------------------------------|-------------------------------|-----------------------------|--------------------------|
|      |            |             |              |             |        | patients with nephritis (mid Sweden, \( n = 153 \))/controls (mid Sweden, \( n = 186 \)) | patients without nephritis (mid Sweden, \( n = 337 \)) |                      |                         |
|      |            |             |              |             |        | Southern Sweden (n = 43)/mid Sweden (n = 121) | Southern Sweden (n = 186) |                      |                         |
| \( CD46 \) | Novel | S13F | c.38C > T | Exon 1 | Signal peptide | 0(0)/0(0) | 0.6(1)/1.0 (2) | 0(0) | Healthy controls | [16] |
| \( CD46 \) | Novel | A219V | c.656C > T | Exon 5 | CCP3 | 2.3(1)/0(0) | 0(0)/0(0) | 0(0) | aHUS, HELLP, GN with C3 deposits and MPGN | [27,39-41] |
| \( CD46 \) | rs35366573 | A353V | c.1058 C > T | Exon 11 | Transmembrane | 5.28(3)/3.0 (10) | 4.8(9) | 6.8(23) | n.d. |                         |
| \( CFH \) | Novel | N29D | c.85A > G | Exon 2 | CCP1 | 0(0)/0(0) | 0(0)/0(0) | 0(0) | aHUS | [42] |
| \( CFH \) | Novel | E40K | c.1198C > A | Exon 9 | CCP7 | 0(0)/0(0) | 0(0)/0(0) | 0.5(1) | n.d. |                         |
| \( CFH \) | Novel | N516K | c.1548T > A | Exon 1 | CCP9 | 0(0)/0(0) | 0(0)/0(0) | 0(0) | n.d. |                         |
| \( CFH \) | Novel | N556S | c.1667A > G | Exon 11 | CCP9 | 0(0)/0(0) | 0(0)/0(0) | 0(0) | aHUS | [43-45] |
| \( CFH \) | Novel | Q950H | c.2850G > T | Exon 18 | CCP16 | 4.7(2)/1.7 (2) | 1.6(3) | 0.6(2) | aHUS | [44,46-48] |
| \( CFH \) | Novel | F960S | c.2879T > A | Exon 18 | CCP16 | 0(0)/0(0) | 0.7(1)/0(0) | 0(0) | aHUS | [44,46-48] |
| \( CFH \) | rs35274867 | N1050Y | c.3148A > T | Exon 20 | CCP18 | 2.3(1)/2.5 (3) | 2.2(4) | 4.7(16) | aHUS, AMD, MPGN2 | [44,46-48] |
| \( CFH \) | rs62625015 | Q1076E | c.3226C > G | Exon 20 | CCP18 | 0(0)/0(0) | 0(0)/0(0) | 0(0) | aHUS | [44,44-48] |

All mutations were found in a mutation frequencies calculated for systemic lupus erythematosus (SLE) patients versus controls and for SLE patients with nephritis versus controls or versus SLE patients without nephritis were not statistically significant according to Fischer’s exact test when calculated for all study participants together or divided into the thee cohorts. aHUS, atypical hemolytic uremic syndrome; AMD, age-related macular degeneration; CCP, complement control protein; HELLP, hemolysis, elevated liver enzymes, and low platelets; n.d., not described; GN, glomerulonephritis; MPGN, membranoproliferative glomerulonephritis; MPGN2, membranoproliferative glomerulonephritis type 2. *Numbering including signal sequence.
mutations and 19 patients without). We also estimated the effect of selected SNPs (frequency higher than 5% in the studied population) by multiple logistic regression analysis corrected for sex and center. SNP haplotypes (frequency higher than 1% in the studied population) were analyzed by a haplotype-based multiple logistic regression test corrected for sex and center. All statistical analyses were performed using PLINK version 1.06 [15]. Max T permutation (10,000 permutations) was used to determine exact single SNP and SNP haplotype P values. A two-tailed P value of 0.05 was considered significant. Only Caucasian patients were included in the SNP and haplotype analyses (four SLE patients and 46 SLE patients were excluded from the southern and mid Sweden cohorts, respectively). No adjustments for multiple comparisons were conducted due to the exploratory nature of this study in which we tested a limited number of comparisons based on a priori hypotheses.

Results

Mutations and polymorphisms identified in the CD46 gene

Analysis of all CD46 exons in 196 patients with nephritis (southern Sweden, n = 43; mid Sweden, n = 153) revealed three nonsynonymous mutations in the coding exons. One of these mutations (S13F), found in heterozygous form in three SLE patients, was localized in the signal peptide and previously found in healthy controls [16] even though the latter was not the case in the current study. The other mutation (A219V), found in one patient, was localized in the CCP3 domain. Furthermore, we found that 11.6% and 5.2% of the patients with nephritis from the southern and mid Sweden cohorts carried the A353V polymorphism. In the patients without nephritis, only 5.0% from southern Sweden and 3.0% from mid Sweden carried the polymorphism; whereas in the control groups, 4.8% and 3.0% from southern Sweden and 3.0% from mid Sweden carried the polymorphism; whereas in the control groups, 4.8% and 6.8% of individuals had the polymorphism. The differences in the A353V polymorphism frequencies between SLE patients and controls or SLE patients with nephritis and those without nephritis or healthy controls were not statistically significant according to Fisher’s exact test (Table 2).

Since several studies identified a specific SNP haplotype block spanning CD46 (CD46<sub>gaac</sub>), which is overrepresented in aHUS patients [17,18], we assessed these SNPs (rs2796267/-652 A > G, rs2796268/-366 A > G, rs1962149/IVS9-78 G > A, rs859705/IVS12+638 G > A, rs7144/c.4070 T > C) in our cohorts. Only haplotypes with frequencies of at least 1% in our cohorts were analyzed. We found weak indications that the aHUS-associated CD46<sub>gaac</sub> haplotype could perhaps be protective for SLE, and in particular for SLE with nephritis, while the CD46<sub>gaac</sub> could represent risk haplotype. The obtained P values, however, were borderline significant (Table 3).

Mutations and polymorphisms identified in the CFH gene

Analysis of all CFH exons in the SLE patients identified seven nonsynonymous mutations. In addition, a novel nonsynonymous mutation (N29D) was found in a healthy individual. All of the mutations occurred in heterozygous state. The Q400K, Q950H, N1050Y and Q1076E mutations were previously described in patients with aHUS while the N29D, N516K and N556S mutations appear to have never been reported. In the current study these three mutations were also found in healthy individuals at similar frequencies to those in SLE patients. Analysis of three common coding SNPs in CFH (V62I/c.184G > A, Y402H/c.1204T > C, E936D/c.2808G > T) showed no significant association with SLE or SLE nephritis. Furthermore, no associations of the haplotypes formed by these SNPs and SLE/SLE nephritis were found.

Mutations in CD46 and CFH influence age at onset of nephritis

Mutations found in CD46 and CFH (listed in Table 2) were found to affect the age at onset of nephritis in the analyzed SLE patients (Figure 1). The effect was statistically significant in the larger cohort from mid Sweden (P = 0.023) and the significance increased when the two cohorts were analyzed simultaneously (P = 0.0085). The median age of nephritis onset in the SLE patients carrying CD46 and CFH mutations in the combined cohorts was 24 years (range 12 to 51) compared with 32 years (range 9 to 84) in the patients free of the mutations. Thus, even though these mutations do not appear to be causative factor for nephritis, they may contribute to the earlier onset of the disease. The multiple regression analysis did not show significant association between onset of nephritis and CD46 (rs2796267/-652 A > G, rs2796268/-366 A > G, rs1962149/IVS9-78 G > A, rs859705/IVS12+638 G > A, rs7144/c.4070 T > C) or CFH (V62I/c.184G > A, Y402H/c.1204T > C, E936D/c.2808G > T) haplotypes.

Discussion

Because complement is intricately involved in SLE and mutations/polymorphisms in complement inhibitors are associated with a number of kidney diseases, we hypothesized that SLE patients, particularly those with nephritis, may also carry such genetic defects. Kidney involvement is common in SLE, occurring in up to 25 to 30% of affected Caucasian adults at some stage during the course of their disease [19]. In most cases, renal disease develops within the first 3 years following
diagnosis. Lupus nephritis still remains a main morbidity and mortality determinant for patients with SLE and the current treatment is not satisfactory considering the rate of success and adverse side effects. If inadequate control of the complement system caused by genetic predisposition is involved in SLE nephritis, it could become an additional indication for use of the emerging complement inhibitors such as eculizumab, which is a monoclonal antibody inhibiting cleavage and activation of C5.

To test our hypothesis we sequenced all exons of the CD46 and CFH genes in two Swedish cohorts of SLE patients. Importantly, we could relate the obtained genetic data to a carefully characterized clinical history of the patients. Interestingly, even though we did not find significant association between the presence of mutations in CD46 and CFH and SLE or SLE nephritis, we observed that these mutations are associated with a younger age at onset of glomerulonephritis. The treatment of all patients with SLE was determined by the clinical manifestations and was similar according to clinical praxis in the rheumatology clinics in southern and mid Sweden, in accordance with EULAR recommendations [20].

Table 3 Associations of haplotypes in CD46 with SLE and SLE nephritis

| Cohort            | CD46 haplotype | Frequency | SLE nephritis vs healthy controls | SLE versus healthy controls |
|-------------------|----------------|----------|-----------------------------------|----------------------------|
|                   |                | All SLE patients | SLE with nephritis | SLE without nephritis | Healthy controls | Odds ratio | P value | Odds ratio | P value |
| Southern Sweden   | GGAAC          | 0.3068    | 0.2457               | 0.3271 | 0.3512 | 0.60 | 0.076 | 0.81 | 0.22 |
| Southern Sweden   | AGAAC          | 0.0901    | 0.0418               | 0.1062 | 0.0573 | 0.66 | 0.52  | 1.53 | 0.17 |
| Southern Sweden   | GAGGT          | 0.0901    | 0.0918               | 0.0895 | 0.0627 | 1.59 | 0.34  | 1.41 | 0.26 |
| Southern Sweden   | AAGGT          | 0.4974    | 0.5707               | 0.473  | 0.5099 | 1.3  | 0.31  | 0.99 | 0.93 |
| Mid Sweden        | GGAAC          | 0.3242    | 0.3251               | 0.3238 | 0.37   | 0.81 | 0.18  | 0.82 | 0.09 |
| Mid Sweden        | AGAAC          | 0.0892    | 0.112                | 0.0723 | 0.0643 | 1.93 | 0.011 | 1.45 | 0.093 |
| Mid Sweden        | GAGGT          | 0.0636    | 0.0555               | 0.0695 | 0.0647 | 0.84 | 0.60  | 0.96 | 0.84 |
| Mid Sweden        | AAGGT          | 0.5117    | 0.5005               | 0.5204 | 0.4875 | 1.07 | 0.68  | 1.12 | 0.34 |
| Combined cohort   | GGAAC          | 0.3184    | 0.3063               | 0.3255 | 0.3633 | 0.76 | 0.047 | 0.82 | 0.044 |
| Combined cohort   | AGAAC          | 0.0895    | 0.096                | 0.0856 | 0.0618 | 1.59 | 0.056 | 1.48 | 0.030 |
| Combined cohort   | GAGGT          | 0.0725    | 0.0644               | 0.0772 | 0.0641 | 1   | 1     | 1.09 | 0.64 |
| Combined cohort   | AAGGT          | 0.5069    | 0.5161               | 0.5017 | 0.4954 | 1.12 | 0.38  | 1.07 | 0.48 |

SLE, systemic lupus erythematosus.

Figure 1 Age at onset of nephritis in systemic lupus erythematosus patients. Median (range) age of nephritis diagnosis for systemic lupus erythematosus patients with or without FH/CD46 mutations, respectively: (A) Southern Sweden cohort, 28 (15 to 42) years and 33 (10 to 68) years; (B) mid Sweden cohort, 22 (12 to 51) years and 32 (9 to 84) years; and (C) combined cohort, 24 (12 to 51) years and 32 (9 to 84) years. Horizontal line, median for each dataset. Statistical significances of differences between patients carrying mutations and those without CD46 and CFH were evaluated by nonparametric Mann-Whitney test with a two-tailed P value.
therefore no reason to believe that different treatment regimens could have affected the time of nephritis onset.

The observed earlier onset of nephritis in SLE patients carrying mutations in CD46 and CFH is consistent with a recently published study showing that FH deficiency accelerates development of lupus nephritis in MRL-lpr mice, which share many features of human SLE including production of autoantibodies and consumptive hypocomplementemia [21]. Histopathologic findings in these animals included marked deposition of immune complexes containing C3 in glomerular subendothelial, mesangial and subepithelial locations and glomerular inflammation with infiltrated neutrophils and macrophages [21]. Complement has complicated and paradoxical roles in SLE. Although deficiencies of early components of the complement cascade are associated with development of SLE due to their role in clearance of dying cells and tissue debris [7] and their importance in development of tolerance [22], clearance of immune complexes [23] and cytokine regulation [24], activation of complement at later stages of C3 and beyond also contributes to the pathogenesis of SLE. Studies using experimental models showed that development of lupus nephritis was dependent on generation of C5a in glomeruli [25] and on the presence of iC3b in glomerular immune complexes [26]. Such observed complement activation in glomerulus was triggered by immune complexes. MCP and FH are both localized to glomerular capillary walls, where they attenuate complement activation under normal conditions. However, this level of protection may be compromised by inherited or acquired deficiency of these proteins.

The A353V polymorphism in MCP has previously been shown to affect the ability of MCP to control the alternative pathway activation [27]. This conservative amino acid substitution in the transmembrane domain did not affect the ability of recombinant MCP to bind C3b/C4b and to act as a cofactor to F1 in the fluid phase. The mutant was defective in its regulatory activity, however, when embedded in the membrane - although the mechanism underlying this impairment of function was not defined. The A353V polymorphism has been identified in several patients with renal pathology such as aHUS, glomerulonephritis with C3 deposits and HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets) [27]. We did not detect association of this polymorphism with SLE in general or SLE nephritis in the current study, however, and we found the polymorphism in 5.8% healthy controls analyzed in the present study and in 3.1% of 192 healthy controls of Caucasian origin included in the study of spontaneous pregnancy loss (manuscript in preparation, Mohlin F, Mercier E, Fremeaux-Bacchi V, Liszewski K, Atkinson JP, Gris JC, Blom AM). The NCBI database estimates 2% frequency for this SNP in European populations [28]. Taken together, these frequencies suggests that the A353V polymorphism in MCP cannot be a strong causative factor for SLE/SLE nephritis, and most probably not aHUS either, but could be a modifying factor in the presence of additional defects in complement regulation often observed in these patients.

The CD46ggaac haplotype has been previously shown to be overrepresented in aHUS patients compared with controls (odds ratio = 2.68). Interestingly, this association was mainly due to the aHUS patients with mutations in CFH, CD46 or CFI (odds ratio = 5.25), whereas aHUS patients without identified mutations in CFH, CD46 or CFI showed no differences with the control group [17]. The functional consequences of the five synonymous SNPs in the CD46ggaac haplotype have not been fully elucidated, but it has been shown that the rs2796267 and the rs2796268 SNPs located in the promoter region are involved in the transcriptional activity potentially due to disruption of the CBF-1/RBP-Jk binding site [17]. Two other SNPs in the CD46ggaac haplotype block are intronic, while the third lies in the 3' UTR. In the current study we found weak indication that the CD46ggaac haplotype could perhaps be protective for SLE, and in particular SLE with nephritis, whereas the CD46ggaac could represent a risk haplotype. These indications must now be assessed in a larger patient material before final conclusions are made.

Several nonsynonymous polymorphisms in CFH have been linked to age-related macular degeneration [29,30] and susceptibility to meningococcal disease [31], but not to rheumatoid arthritis [32] or coronary heart disease [33]. A large number of studies have shown that I62V polymorphism in CCP1 of FH affects its F1 cofactor activity and ability to accelerate decay of convertases [34,35] and that the Y402H polymorphism in CCP7 affects binding of FH to several ligands such as C-reactive protein, DNA, dying cells and heparin [36,37]. The effect of the D936E polymorphism in CCP16, however, has not yet been analyzed. In the current study we did not detect any significant associations with these three SNPs in CFH nor any of the haplotypes thereof. This finding is consistent with a recent publication assessing association of genetic variants in CFH with SLE susceptibility [38]. The authors studied 60 SNPs covering CFH and FH-related genes for association with SLE in over 15,000 case-control subjects from four ethnic groups. They found significant allelic associations with SLE in European Americans and African Americans, which could be attributed to an intronic CFH SNP and intergenic SNP between CFHR1 and CFHR4 rather than the exonic SNPs we studied.
Conclusions

Taken together, SLE and SLE nephritis do not appear to be associated with frequent mutations in CD46 or CFH as reported for some other kidney diseases, but these mutations are likely to affect the year of onset of nephritis. Furthermore, the role of CD46 haplotypes still remains to be elucidated in a larger patient cohort.

Abbreviations
ahUS: atypical hemolytic uremic syndrome; CCP: complement control protein; FH: factor H; Fl: factor I; MOP: membrane cofactor protein; SLE: systemic lupus erythematosus; SNP: single nucleotide polymorphism; UTR: untranslated region.

Acknowledgements
The authors would like to acknowledge the financial support of the Söderberg Foundation Council (S2009-68X-14028-06-3, K2011-52X-12672-14-3 and 2008-2201), the Swedish Foundation for Strategic Research, the Swedish Rheumatism Association, Swedish Society of Medicine, the National Board of Health and Welfare and Skåne University Hospital, and the Swedish Heart-Lung Foundation, as well as Osterlund, Greta and Johan Kock, King Gustaf V’s 80th Birthday, Knut and Alice Wallenberg, Inga-Britt and Arne Lundberg, Professor Nanna Svartz and Pharmacist Hedberg Foundations.

Author details
1Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Kloo kagan 3, SE-221 85 Lund, Sweden. 2Section of Medical Protein Chemistry, Department of Laboratory Medicine Malmö, Lund University, S-205 02 Malmö, Sweden. 3Section of Diabetes and Endocrinology, Department of Clinical Sciences Malmö, Lund University, S-205 02 Malmö, Sweden. 4Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institute, S-171 76 Stockholm, Sweden. 5Section of Rheumatology, Department of Medical Sciences, Uppsala University, SE-751 08 Uppsala, Sweden. 6Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund University, Sövdegatan 23, 223 62 Lund, Sweden.

Authors’ contributions
AMB initiated the collaborative project, designed the study, monitored data collection, designed the statistical analysis plan, and drafted and revised the paper. AJ collected clinical data and samples for patients in Lund, contributed to design of the study and revised the draft paper. SCN cleaned and assembled the data, performed statistical analyses, contributed to the design of the study and revised the draft paper. EA performed statistical analyses and revised the draft paper. ES collected clinical data and samples for patients in Lund, contributed to design of the study and revised the draft paper. IG collected clinical data and samples for patients in Uppsala and revised the draft paper. KGE collected clinical data and samples for patients at Karolinska Hospital, contributed to design of the study and revised the draft paper. LR collected clinical data and samples for patients in Uppsala, contributed to design of the study and revised the draft paper. GN collected clinical data and samples for patients in Lund, contributed to design of the study and revised the draft paper. LR collected clinical data and samples for patients in Uppsala, contributed to design of the study and revised the draft paper. Gs collected clinical data and samples for patients in Lund, contributed to design of the study and revised the draft paper. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

References
1. Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, Sun X, Omtmann W, Kosoy R, Ferreira RC, Nordmark G, Gunnarsson I, Svenungsson E, Padyukov L, Sturfelt G, Jönsen A, Bengtsson AA, Rantapää-Dahlgren S, Baechler EC, Brown EE, Alarcón GS, Edberg JC, Ramsey-Goldman R, McGowan G Jr, Reveille JD, Vilä LM, Kimberly RP, Marzi S, Petri MA, Lee A, Gergesek Pk, et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 2009, 41:1228-1233.
2. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, de Bakker PI, Le JM, Lee HS, Batillaliva F, Li W, Masters SL, Booty MG, Carulli JP, Padyukov L, Alfredsson L, Klareskog L, Chen WN, Amos CI, Criswell LA, Seldin MF, Kastner DL, Gergesek PK. ST4A and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2011, 365:977-986.
3. Sigurdsson S, Nordmark G, Göring HH, Lindroos K, Wiman AC, Sturfelt G, Jönsen A, Rantapää-Dahlgren S, Möller B, Kere J, Koskenmies S, Widen E, Eloranta ML, Julkunen H, Kristjansdottir H, Steinson K, Alm G, Ronnlöbl M, Svenäen AC. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005, 76:528-537.
4. Sandling JK, Garnier S, Sigurdsson S, Wang C, Nordmark G, Gunnarsson I, Svenungsson E, Padyukov L, Sturfelt G, Jönsen A, Bengtsson AA, Truedsson L, Eriksson C, Rantapää-Dahlgren S, Målarstig A, Strawbridge R, Hamsten A, Criswell LA, Graham RR, Behrens TW, Eloranta ML, Alm G, Ronnlöbl M, Svenäen AC. A candidate gene study of the type I interferon pathway implicates IF Mich RE and IL8 as risk loci for SLE. Eur J Hum Genet 2011, 19:479-484.
5. Kaiser R, Criswell LA. Genetics research in systemic lupus erythematosus for clinicians: methodology, progress, and controversies. Curr Opin Rheumatol 2010, 22:119-125.
6. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010, 11:785-797.
7. Truedsson L, Bengtsson AA, Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity 2007, 40:560-566.
8. Molino C, Fabbian F, Longhin C. Clinical approach to lupus nephritis: recent advances. J Intern Med 2009, 266:447-453.
9. Servais A, Noël LH, Dragon-Durey MA, Gubler MC, Rémy P, Buob D, Cordonnier C, Makdassi R, Jaber W, Boulanger E, Lesavre P, Frémeaux-Bacchetti V. Heterogeneous pattern of renal disease associated with homozygous factor H deficiency. Hum Pathol 2011, 42:1305-1311.
10. Nilsson SC, Sim RB, Lea SM, Fremaux-Bacchetti V, Bom AM. Complement factor H in health and disease. Mol Med 2011, 17:1611-1620.
11. Hom G, Graham RR, Modeb K, Taylor KE, Omtmann W, Garnier S, Lee AT, Chung SA, Ferreira RC, Pani PV, Ballinger DG, Kosoy R, Demirci FY, Karnmbih M, Kha AH, Tan C, Gunnarsson I, Bengtsson AA, Rantapää-Dahlgren S, Petri M, Marzi S, Seldin MF, Ronnlöbl M, Svenäen AC, Criswell LA, Gergesek PK, Behrens TW. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. Curr Opin Rheumatol 2010, 22:125-131.
12. International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN), Harkey JB, Alarcón-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moiser KL, Tsao BF, Vyse TJ, Langefeld CD, Nahr JK, Guthridge JH, Cobb BL, Mikel DB, Marion MC, Williams AH, Diver J, Wang W, Frank SG, Namjou B, Gabriel SB, Lee AT, Gergesek PK, Behrens TW, Kao AH, Ronnlöbl M, Svenäen AC, Criswell LA, Gergesek PK, Behrens TW. Association of systemic lupus erythematosus with CBIR3-BLK and ITGAM-ITGAX. N Engl J Med 2008, 358:900-909.
13. Wing SJ, Fazel M, Shaw P, Koutsouraki M, Townsend E, Aitken PM, Farmers PA, Edberg JC, Roux JD, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, HLA-A1542 and other loci. Nat Genet 2008, 40:204-210.
14. Ding Y, Tsao BP. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol 2010, 6:683-692.
15. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller KG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
16. Purcell S, Neale B, Todd-Brown K, Thomas L, Fererra MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Shain PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007, 81:559-575.
17. Kusuhara K, Sasaki Y, Nakao F, Iihara K, Hattori H, Yamashita S, Nihei K, Koide N, Aiba H, Takeshita K, Hara T. Analysis of measles virus binding
sites of the CD46 gene in patients with subacute cerebrovascular penicaphlebitis. J Infect Dis 2000, 181:1447-1449.

17. Esparza-Goldilor J, Gococochea de Jorge E, Bull A, Carreras Berges L, Lopez-Trascas M, Sanchez-Cornel P, Rodriguez de Cordoba S. Predisposition to atypical hemolytic uraemic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 13q22. Hum Mol Genet 2005, 14:703-712.

18. Fremeaux-Bacchi V, Kemp EJ, Goodship, JA, Dragon-Durey MA, Strain L, Loiart C, Deng HW, Goodship, TH. The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts. J Med Genet 2005, 42:852-856.

19. Stahl-Hallenge C, Jonsen A, Nived O, Sturfelt G: The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. Hum Mol Genet 2009, 18:3452-3461.

20. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, Font J, Jönsen

21. Davies KA, Hird V, Stewart S, Sivolapenko GB, Jose P, Epenetos AA, Gilboe IM, Houssiau F, Huizinga T, Isenberg D, Kallenberg CG, Khamashta M, Eloranta ML, Bengtsson AA: Distinct and separable roles of the complement regulatory system in development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. J Immunol 2000, 35:2496-2506.

22. Carroll MC: A protective role for innate immunity in systemic lupus erythematosus. Nat Rev Immunol 2004, 4:825-831.

23. Davies KA, Hird V, Stewart S, Sivolapenko GB, Jose P, Epenetos AA, Gilboe IM, Houssiau F, Huizinga T, Isenberg D, Kallenberg CG, Khamashta M, Eloranta ML, Bengtsson AA: Distinct and separable roles of the complement regulatory system in development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. J Immunol 2000, 35:2496-2506.

24. Bello L, Osaie I, Puri T, Lambris JD, Haas M, Quigg RJ: CSa promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol 2005, 35:6081-3091.

25. Bello L, Osaie I, Puri T, Lambris JD, Haas M, Quigg RJ: CSa promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol 2005, 35:6081-3091.

26. Alexander JJ, Aneziokoro OG, Chang A, Hack BK, Markaryan A, Jacob A, Bierman AM: The factor H variant associated with age-related macular degeneration (His-384) and the non-disease-associated form bind differentially to C-reactive protein, fibromodulin, DNA, and necrotic cells. J Biol Chem 2007, 282:10894-10900.

27. Laine M, Jarva H, Seistonen S, Haapasaalo K, Lehtinen MJ, Lindeman N, Anderson DH, Johnson PT, Jarvela I, Jokiranta TS, Hagemeijer G, Immonen I, Méri S: Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol 2007, 178:3831-3836.

28. Zhao J, Wu H, Khosravi M, Cui H, Qian X, Kelly J, Kaufman KM, Langefeld CD, Williams AH, Comeau ME, Ziegler JT, Marion MC, Adler A, Glenn SB, Alarcón-Riquelme ME, BOLPURUS Network, GENES Network, Pons-Estel BA, Hardy JB, Bae SC, Bang SJ, Cho SK, Jacob CO, Vyse TJ, Newbold TR, Gaffney PM, Moser KL, Kimberly RP, Edberg JC, Brown ES: Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PloS Genet 2011, 7:e1002079.

29. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresolin N, Cassis L, Gamba S, Brioschi S, Daina E, Remuzzi G, Noris M, Goodship TH, Atkinson JP: Membrane cofactor protein mutations in atypical hemolytic uraemic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 2008, 112:624-632.

30. NCBI Database. http://www.ncbi.nlm.nih.gov.

31. Hageman GS, Anderson DH, Johnson LV, Talnud PJ, Ireland H, Kvivsmal M, Marmot M, Hughes AD, Thorn S, Eshrim S, Whittaker JC, Smeeth L, Lawlor DA, Humphries SE, Hingorani AD: Genetic variation in complement factor H and risk of coronary heart disease: eight new studies and a meta-analysis of around 48,000 individuals. Atherosclerosis 2010, 213:184-190.

32. Pechtl I, Kavanagh D, McIntosh N, Harris CL, Barlow PN: Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities. J Biol Chem 2011, 286:11082-11090.

33. Torajada A, Montes T, Martínez-Barricante R, Morgan BP, Harris CL, de Cordoba SR: The disease-protective complement factor H alloglycine variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. Hum Mol Genet 2009, 18:3452-3461.
46. Abrera-Abeleda MA, Nishimura C, Smith JL, Sethi S, McRae JL, Murphy BF, Silvestri G, Skerka C, Józsi M, Zipfel PF, Hageman GS, Smith RJ. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet 2006, 43:582-589.

47. Boon CJ, Klevering BJ, Hoyng CB, Zonneveld-Vrieling MN, Nabuurs SB, Blokland E, Cremers FP, den Hollander AI. Basal laminar drusen caused by compound heterozygous variants in the CFH gene. Am J Hum Genet 2008, 82:516-523.

48. Richards A, Buddles MR, Donne RL, Kaplan BS, Kirk E, Venning MC, Tielemans CL, Goodship JA, Goodship TH. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am J Hum Genet 2001, 68:485-490.

doi:10.1186/ar3539

Cite this article as: Jønsen et al. Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus. Arthritis Research & Therapy 2011 13:R206.